Valuation: Cosmos Holdings Inc.

Market Cap 1.27Cr 1.1Cr 1.02Cr 93.64L 1.76Cr 120.76Cr 1.79Cr 12Cr 4.71Cr 60Cr 4.75Cr 4.65Cr 201.21Cr P/E 2026 *
22.4x
P/E 2027 * 3.19x
Enterprise Value 1.27Cr 1.1Cr 1.02Cr 93.64L 1.76Cr 120.76Cr 1.79Cr 12Cr 4.71Cr 60Cr 4.75Cr 4.65Cr 201.21Cr EV / Sales 2026 *
0.15x
EV / Sales 2027 * 0.11x
Free-Float
63.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 26/02/2016
Director of Finance/CFO 43 11/11/2020
Chief Operating Officer 56 01/02/2023
Director TitleAgeSince
Director/Board Member 58 13/01/2014
Chairman 60 26/02/2016
Director/Board Member 59 18/11/2016
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 1.27Cr
+1.18%+2.77%+31.60%+105.41% 10TCr
+0.33%+3.11%+50.68%+157.89% 5.54TCr
+0.17%+0.68%+3.50%+274.68% 2.42TCr
+0.12%-0.83%-12.37%-13.90% 829.29Cr
+2.21%+1.79%-30.23%-26.46% 753.35Cr
+0.59%-1.84%-9.64%-21.74% 674.62Cr
0.00%+0.19%+19.28%+13.92% 618.62Cr
0.00%-4.36%-2.55%+20.79% 507.01Cr
+1.20%-1.94%-5.61%-6.75% 368.7Cr
Average -0.07%+1.08%+4.96%+55.98% 2.43TCr
Weighted average by Cap. +0.68%+3.23%+26.48%+118.02%

Financials

2026 *2027 *
Net sales 8.43Cr 7.3Cr 6.82Cr 6.23Cr 12Cr 804Cr 12Cr 80Cr 31Cr 402.22Cr 32Cr 31Cr 1.34TCr 11Cr 9.59Cr 8.97Cr 8.19Cr 15Cr 1.06TCr 16Cr 105.13Cr 41Cr 528.66Cr 42Cr 41Cr 1.76TCr
Net income - -
Net Debt - -
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-

Quarterly revenue - Rate of surprise